-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $119

Benzinga·12/09/2025 16:40:48
语音播报
Barclays analyst Etzer Darout maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $70 to $119.